Literature DB >> 8260306

Sevoflurane does not increase intracranial pressure in hyperventilated dogs.

H Takahashi1, K Murata, K Ikeda.   

Abstract

We have measured the effects of 0.5, 1.0 and 1.5 MAC (minimum alveolar concentration) end-tidal concentrations of sevoflurane on intracranial pressure (ICP), cerebral perfusion pressure (CPP), mean arterial pressure (MAP), central venous pressure and heart rate in hypocapnic dogs (PaCO2 3.2-3.7 kPa) and compared the data with those produced by equi-MAC concentrations of enflurane and halothane. Enflurane and halothane caused small but significant increases in ICP at 0.5, 1.0 and 1.5 MAC, but there were no changes with sevoflurane. However, sevoflurane caused a considerable decrease in MAP with consequent decrease in CPP. We conclude that sevoflurane should be a suitable agent for neuroanaesthesia and is preferable to either enflurane or halothane.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8260306     DOI: 10.1093/bja/71.4.551

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

1.  A Fulminant Case of Leptomeningeal Carcinomatosis Secondary to Esophageal Adenocarcinoma.

Authors:  Banu Tasci Fresko; Meltem Topalgokceli Selam; Hatice Tuzlali; Burcin Batman; Oktar Asoglu
Journal:  J Gastrointest Cancer       Date:  2016-03

2.  Changes in the cerebral arteriovenous oxygen content difference by surgical incision are similar during sevoflurane and isoflurane anaesthesia.

Authors:  T Inada; K Shingu; M Uchida; S Kawachi; K Tsushima; T Niitsu
Journal:  Can J Anaesth       Date:  1996-10       Impact factor: 5.063

Review 3.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

4.  Transient changes in white matter microstructure during general anesthesia.

Authors:  Cheuk Y Tang; Victoria X Wang; Min Yin Lun; Joshua S Mincer; Johnny C Ng; Jess W Brallier; Arthur E Schwartz; Helen Ahn; Patrick J McCormick; Tommer Nir; Bradley Delman; Mary Sano; Stacie G Deiner; Mark G Baxter
Journal:  PLoS One       Date:  2021-03-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.